HomeCompareRNWK vs ABBV

RNWK vs ABBV: Dividend Comparison 2026

RNWK yields 547.95% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RNWK wins by $125545.45M in total portfolio value
10 years
RNWK
RNWK
● Live price
547.95%
Share price
$0.73
Annual div
$4.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$125545.55M
Annual income
$92,380,482,230.31
Full RNWK calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RNWK vs ABBV

📍 RNWK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRNWKABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RNWK + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RNWK pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RNWK
Annual income on $10K today (after 15% tax)
$46,575.34/yr
After 10yr DRIP, annual income (after tax)
$78,523,409,895.76/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RNWK beats the other by $78,523,388,839.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RNWK + ABBV for your $10,000?

RNWK: 50%ABBV: 50%
100% ABBV50/50100% RNWK
Portfolio after 10yr
$62772.83M
Annual income
$46,190,253,501.03/yr
Blended yield
73.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RNWK
Analyst Ratings
1
Buy
Consensus: Buy
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RNWK buys
0
ABBV buys
0
No recent congressional trades found for RNWK or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRNWKABBV
Forward yield547.95%3.06%
Annual dividend / share$4.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$125545.55M$102.3K
Annual income after 10y$92,380,482,230.31$24,771.77
Total dividends collected$122722.76M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: RNWK vs ABBV ($10,000, DRIP)

YearRNWK PortfolioRNWK Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$65,495$54,794.52$11,550$430.00+$53.9KRNWK
2$405,475$335,396.34$13,472$627.96+$392.0KRNWK
3$2,374,450$1,940,591.70$15,906$926.08+$2.36MRNWK
4$13,161,259$10,620,596.57$19,071$1,382.55+$13.14MRNWK
5$69,099,868$55,017,321.36$23,302$2,095.81+$69.08MRNWK
6$343,894,398$269,957,539.26$29,150$3,237.93+$343.87MRNWK
7$1,623,590,885$1,255,623,879.22$37,536$5,121.41+$1623.55MRNWK
8$7,277,465,834$5,540,223,587.11$50,079$8,338.38+$7277.42MRNWK
9$30,995,389,120$23,208,500,677.65$69,753$14,065.80+$30995.32MRNWK
10$125,545,548,589$92,380,482,230.31$102,337$24,771.77+$125545.45MRNWK

RNWK vs ABBV: Complete Analysis 2026

RNWKStock

RealNetworks, Inc. provides digital media software and services in the United States, Europe, and internationally. Its Consumer Media segment offers RealPlayer media player, a software that enables consumers to discover, play, download, manage, and edit digital video, stream audio and video, download and save photos and videos from the web, transfer and share content on social networks, and edit their own photo and video content. This segment also licenses its codec technology to electronic equipment, microchip, and integrated circuit manufacturers. The company's Mobile Services segment provides digital media services to mobile and online service providers as software as a service offerings, which include intercarrier messaging services; KONTXT, a text message management, anti-spam, and classification product; ringback tone that enables callers to hear subscriber-selected music or messages; business intelligence, and subscriber management and billing for the carriers; RealTimes, a photo and video sharing platform that offers to wireless carriers for integration in their hosted cloud solutions; and SAFR, a computer vision platform. Its Games segment develops, publishes, and distributes casual games, including time-management, board, card, puzzle, word, and hidden-object games. It offers its casual games through mobile devices, digital downloads, and subscription play. RealNetworks, Inc. provides its products and services through direct and indirect channels comprising public relations, trade shows, events, and speaking opportunities; online channels, including social media; third party distribution partners; and third-party distribution channels, such as application storefronts, search engines, online portals, and content publishers. It offers its software and services to consumers, mobile carriers, device manufacturers, system integrators, and other businesses. The company was incorporated in 1994 and is headquartered in Seattle, Washington. As of December 21, 2022, RealNetworks, Inc. was taken private.

Full RNWK Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RNWK vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RNWK vs SCHDRNWK vs JEPIRNWK vs ORNWK vs KORNWK vs MAINRNWK vs JNJRNWK vs MRKRNWK vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.